JAMA Neurology

@jamaneurology.com

264 Followers 94 Following

JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. 🌐 JAMANeurology.com

JAMA Neurology: "Trends in Dementia Prevalence Across Latin America and the Caribbean" (July 13, 2026). Bar graph compares age/sex-standardized dementia prevalence (2003-06 vs. 2016-20) in Cuba, Dominican Republic, Peru, Mexico, Puerto Rico. Most countries show increases; Puerto Rico highest, Cuba slightly decreased.
Diagram. A: Iterative R&D feedback loop: computational modeling, platform dev, window-of-opportunity trials, go/no-go decision, advanced clinical trials. B: 5 layers of glioblastoma gene therapy specificity: Administrative, Cell entry, Transcriptional, Posttranscriptional, Functional. C: Innovations: Long-term catheters, Synthetic biology, Combinatorial strategies.
JAMA Neurology graph: 'Trends in Dementia Prevalence Across Latin America and the Caribbean'. Bar graph shows age- & sex-standardized dementia prevalence (2003-2006 vs. 2016-2020) in 5 countries. Prevalence increased in Peru, Mexico, and Puerto Rico, while slightly decreasing in Cuba and Dominican Republic.
JAMA Figure 2: Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. Panels A-C display beta-amyloid plaques & clearance in brain tissue; D-F show phosphorylated tau pathology, reactive microglia & astrocytes at various magnifications. Published July 12, 2026.
Figure 1. Clinical Imaging of a Spinal Cord Cleft. A) Axial T2-weighted MRI shows a bright C-shaped spinal canal with a pink arrow pointing to a dark cleft within. B) Intraoperative ultrasound shows complex internal spinal structures with a pink arrow pointing to an anomaly.
Three box plots show biomarker discrimination by Aβ-PET positivity (Aβ+/Aβ-) and TBI group. (A) p-tau217/Aβ42, (B) p-Tau217, (C) Aβ42/Aβ40. All are log scales. X-axis groups: None, LOC 0-5 min, LOC >5 min, each split by Aβ-/Aβ+. P-values often <.001, indicating significant differences.
Figure 1: Tongue Appearance Before & After Treatment. A: Atrophied tongue at presentation, showing pale, coated surface. B: Resolution of atrophy, displaying a pinker, healthier tongue.
JAMA academic article titled 'Stopping Alzheimer Disease 50 Years of Progress' by John K. Hsiao, MD. Published online June 22, 2026. A 'PERSPECTIVE' piece, the page is filled with dense text discussing the history and research on Alzheimer's disease.
Four scatter plots show standardized frontotemporal volume vs CSF markers. TMEM106B positively correlates (β>0, P≤.002) and NFL negatively correlates (β<0, P≤.02) with volume across discovery and validation cohorts.
Diagram of an acoustic processing pipeline. Inputs (Acoustic noise, Patient/Physician speech) lead to Raw recording, then 30-sec window recordings, and Segment-level whisper features. These feed into XGBoost for Segment-level prediction, aggregated to Recording-level prediction.
Diagram of an acoustic processing pipeline. Inputs (Acoustic noise, Patient/Physician speech) lead to Raw recording, then 30-sec window recordings, and Segment-level whisper features. These feed into XGBoost for Segment-level prediction, aggregated to Recording-level prediction.
JAMA Neurology editorial: "Clinical Conversations as a Window Into Cognitive Impairment" by Gabriela Meade, PhD, CCC-SLP, and Hugo Botha, MBChB. Published online June 15, 2026. doi: 10.1001/jamaneurol.2026.1863.
JAMA Neurology: 'Neurological Manifestations in Adult Survivors Ebola Virus Disease'. Figure 3 presents four line graphs of GNE and CNS scores over 100 months, comparing Ebola survivors and contacts, grouped by age (<40 vs. ≥40). Scores vary for both groups.
Diagram of an acoustic processing pipeline. Inputs (Acoustic noise, Patient/Physician speech) lead to Raw recording, then 30-sec window recordings, and Segment-level whisper features. These feed into XGBoost for Segment-level prediction, aggregated to Recording-level prediction.
Flow diagram showing an acoustic processing pipeline for patient-physician interactions. Acoustic noise, patient, and physician speech combine into raw recordings. These are windowed, features extracted, fed into an XGBoost model (represented as a tree), and output segment/recording-level predictions.
JAMA Neurology: Neurological Manifestations in Adult Survivors Ebola Virus Disease. Four graphs display longitudinal GNE & CNS scores over 100 months for Ebola survivors & contacts, separated by age (<40, ≥40) at enrollment. Scores generally decline or stabilize over time.
RCT results on Middle Meningeal Artery Embolization (MMAE) for chronic subdural hematoma. 376 patients (mean age 70) were randomized. A graph shows the MMAE group had a significantly lower failure probability (11.6%) compared to the standard care group (22.1%) over 183 days.
Kaplan-Meier survival curve showing survival probability over 40 years for individuals with GBA1, LRRK2 variants, and those without. LRRK2 variants show higher survival probability over time compared to GBA1 PD risk, GBA1 GD-causing, and no variant groups.
Figure 3. Line graphs from JAMA Neurology show GNE and CNS scores over time (months since EVD symptoms) for Ebola survivors & contacts, stratified by age (<40, ≥40). Survivors' scores are initially higher & decrease, contacts' scores are low & stable.
A Kaplan-Meier survival curve shows survival probability vs. time (0-40 y) for different genetic variants. LRRK2 variants (blue line) show the highest survival, while GBA1 PD risk variants (dark gray) and No variant (light gray) show the lowest. A table below shows the number at risk for each group over time.
JAMA Neurology Figure 3: Four line graphs show longitudinal General Neurological Examination (GNE) and Central Nervous System (CNS) scores over 100 months post-Ebola symptoms for survivors & contacts, grouped by age (<40, ≥40). Scores typically stabilize or decrease over time.
Kaplan-Meier survival curve showing survival probability over 40 years for individuals with GBA1 PD risk, GBA1 GD-causing, LRRK2, or no variants. LRRK2 variants have the highest survival probability, GBA1 variants the lowest. A 'No. at risk' table is included.
Kaplan-Meier curve for GBA1, LRRK2 variant, & no variant groups. Y-axis: Survival probability, X-axis: Time (years). LRRK2 variants show highest survival; GBA1 GD-causing variants show lowest. A table below lists number at risk for each group over 40 years.
JAMA Neurology study on personalized BP targeting after stroke. 440 patients (207M/233F, avg 75y) randomized. Intervention group (215 patients) had targeted BP, control (225 patients) standard care. Intervention group showed significantly better functional outcomes (60% vs 47%).
JAMA Neurology RCT: Tenecteplase vs Alteplase for stroke. In 218 adults, Tenecteplase (10.3% reperfusion) showed higher early substantial reperfusion vs Alteplase (3.6%). Bar chart illustrates findings. Study from 18 hospitals in Japan.
Kaplan-Meier survival curve showing GBA1 & LRRK2 variants vs. no variants. Y-axis: Survival probability, X-axis: Time since onset (y). LRRK2 variants show higher survival probability than GBA1 GD-causing, GBA1 PD risk, or no variant groups.
Box-and-whisker plots show P-Tau217/Aβ42 ratio (left) and P-Tau217 concentration (right) by amyloid status (A-, A+) for two cohorts (Mayo Clinic, WRAP/WADRC). A+ groups generally have higher values. Blue lines are Mayo Clinic, orange are FDA-cleared cut points.
Figure 2: MRI of the bilateral oculomotor nerve (cisternal segment) showing structures with arrowheads, and a corresponding illustration of nerve pathways to two eyes, labeled CN III (R), CN III (L), originating from Oculomotor (CN III) nuclei.
Medical illustration explaining peripheral neuropathy. It shows healthy and damaged nerve cells, a foot with highlighted nerves, and a hand using a blood glucose meter (reading 98). Text details neuropathy, its diabetes link, symptoms, and options for treatment and prevention.
JAMA Neurology RCT: Tenecteplase vs Alteplase for Acute Ischemic Stroke. 218 patients (mean 77.1y, 126M/92F) in 18 Japanese hospitals. Tenecteplase (10.3%) increased early substantial reperfusion vs Alteplase (3.6%). Bar graph confirms Tenecteplase's higher efficacy.
Figure 2 shows an MRI of the bilateral oculomotor nerve (cisternal segment) with black arrowheads and an illustration of the bilateral oculomotor nerve with CN III (R), CN III (L), and Oculomotor (CN III) nuclei.
JAMA Neurology presents an RCT on neurological teleconsultations. Population: 378 males, 605 females, median age 55. Intervention: 983 randomized, 514 used telemedicine. Findings: Neurological teleconsultation group 38.3% vs. standard care 50.7%.
Kaplan-Meier curves show time to relapse in pediatric (A) and overall populations (B). Ecopipam vs. placebo groups, measuring 'Participants maintaining benefit, %' over 'Time, wk'. HR, CI, and P values are shown.
JAMA Neurology presents an RCT: Early vs Delayed Extubation After Thrombectomy for Acute Ischemic Stroke. Population: 77 male, 97 female. Intervention: 174 patients randomized. Findings: Early extubation didn't improve functional independence. mRS score 0-2 at 90 d shown.
Two brain scans are displayed side by side. (A) shows the Initial DWI showing punctate lesion. (B) shows the Follow-up DWI showing new ischemic lesion.
Line graphs show changes in biomarker concentrations(p-tau217, S100B, NSE, BD-tau, NfL, GFAP) after match participation in relation to total headers. Each graph plots concentration vs. number of headers, showing slight increases with header count, along with beta and P-values.
Image shows preprocedural angiographic and ultrahigh-resolution photon-counting computed tomographic angiographic (PCCTA) findings prior to left external carotid artery angioplasty. A conventional DSA, B cinematic rendering using ultrahigh-resolution PCCTA.
Six line graphs show biomarker changes post-match relative to header count. Graph A: 'Change in p-tau217 concentration,' beta=0.085, P=.01. Graph B: 'Change in S100B concentration,' beta= 0.073, P=.02. Remaining graphs show similar data for NSE, BD-tau, NfL, and GFAP.
Table: Review of Cadaver-Derived Human Growth Hormone Recipients. Columns include case number, cognitive impairment, amyloid pathology, tau pathology, criteria for Alzheimer's, and amyloid/tau pathology for 2024@4 & 2026@7 cases.
Figure 1. Simulation: Graphs show data aggregation's effects on data representation and regression statistics. Individual-level data contrasts anti-amyloid agent and placebo, data reduction by quantile aggregation, and quantile-aggregated data.
The image contains four graphs labeled A-D. Graph A shows EBNA-1 peptide antibody titers over time. Graph B shows the cumulative number of time points with high-level EBNA-1 peptide antibody titers. Graphs C and D show forest plots.
Four photos show a woman demonstrating benign essential blepharospasm relief via music. A: Oboe playing, relieved. B: Singing, relieved. C: Straw blowing, active. D: Speaking, active. Text: Producing music@number, blowing/fingering@number.
Line graphs show change in biomarker concentrations after match participation versus total headers. Graphs show changes in p-tau217, S100B, NSE, BD-tau, NfL, and GFAP concentrations with respect to the number of headers.
Two bar graphs show the factor weights of sleep-wake cycle metrics that form two components as predictors of incident dementia in the UK Biobank Study. Metrics include daytime activity, sleep, chronotype and transition probabilities with weight scales from -0.8 to 0.8.
JAMA Neurology info sheet titled, "RCT: Fixed-Dose Tavapadon for Early Parkinson Disease." It includes: Population: 342 male, 187 female; Intervention: 529 randomized participants; Findings: statistically significant improvement; Primary Outcome: Change from baseline to week 26.
Figure 2 shows line graphs of biomarker concentrations after match participation, related to the number of headers. Graphs show changes in p-tau217, S100B, NSE, BD-tau, NfL, and GFAP concentrations, each with a line indicating the trend.
JAMA Neurology presents RCT: Tavapadon as Adjunctive Treatment for Parkinson Disease. Population: 321 Male, 186 Female, mean age 64.9y. Intervention: 507 randomized, 487 analyzed. Findings show statistically significant increase in daily good-on-time with Tavapadon vs placebo.
An excerpt from JAMA Neurology Year in Review, 2025 by S. Andrew Josephson, MD. It shows manuscript data, acceptance rates, review times, impact factor, information dissemination, and top 3 articles by views/downloads.
Bar graph titled 'Figure 2. Bar Graph Showing Age Bracket Performance of Age-at-Onset (AAO) Criteria for Genetic Testing in Parkinson Disease (PD).' X-axis: Age at onset, y. Y-axis: PPV. ROPAD and PD GENEration are represented.
Two-part image: A) 'Intraoperative anteroposterior view' shows an x-ray with medical apparatus visible and two highlighted spots via black and yellow arrowheads. B) 'Postoperative view' displays a skull scan with a marked area via a black arrowhead and a magnified view.
Two brain scans are displayed side by side. (A) shows the Initial DWI showing punctate lesion. (B) shows the Follow-up DWI showing new ischemic lesion.
Four graphs display composite z scores over 24 months. Graphs A & C show 'No exercise' vs 'Exercise', while B & D show 'No IRVR' vs 'IRVR'. Participant numbers are noted under each graph at months: 0, 6, 12, 18, and 24.
Bar graph titled 'Figure 2. Bar Graph Showing Age Bracket Performance of Age-at-Onset (AAO) Criteria for Genetic Testing in Parkinson Disease (PD).' X axis shows 'Age at onset, y' with PPV on the Y axis. ROPAD and PD GENERation are displayed.
Figure 1: "Bar Chart and Line Graph of Demographic Characteristics." Graph A shows the distribution of diagnoses by sex. Graph B shows the mean (SD) age at diagnosis for FND total, FND-motor, FND-seizure, FND-sensory, FND-mixed.
Article titled "Incidence and Prevalence of Dementia With Lewy Bodies: A Systematic Review and Meta-Analysis" by Daniele Urso, Stefano Giannoni-Luza, Thomas Giannelli, and others in JAMA Neurology, published May 11, 2026.
Diagrams illustrate 'Assessment based on N=1 Collaborative VARIANT guidelines' and 'Assessment based on splice-switching framework,' showing exon skipping, knockdown, wild-type upregulation, and splice correction. Text includes: BRAT1@1, TNPO2@1, AIMP1@1.
Two brain scans are displayed side by side. (A) shows the Initial DWI showing punctate lesion. (B) shows the Follow-up DWI showing new ischemic lesion.
Line graph showing incidence rates per 100 person-years versus mean follow-up in years, illustrating outcomes like Dementia with Lewy bodies, Multiple system atrophy, Parkinson's disease, and Total incidence.
JAMA Research Summary: Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke. It shows outcomes, trial details, and participant info. Tirofiban had a 63.8% success rate vs. 52.2% for the placebo. Text@1, Text@2